Physiologically-based pharmacokinetic modeling to support submission of brigimadlin (BI 907828) in dedifferentiated liposarcoma

PAGE 33 (2025) Abstr 11489
Kanacher T, Busse D, Sailer R, Sjögren E, Mezzalana E, Pellowe M, Chenel M, Gómez-Mantilla JD, Ince I.
AutomationConferenceDDIMIDDOncologyRegulatory interactionsTrial design and analysis

Pharmetheus Affiliates

Portrait-of-Tobias-Kanacher-Pharmetheus
Senior Director, MIDD Consultant

Tobias Kanacher

See bio
Portrait-of-Erik-Sjogren_Pharmetheus-2
Principal Director, PBPK & PBBM Scientific Lead

Erik Sjögren

See bio
Portrait-of-Enrica-Mezzalana_Pharmetheus-1
Senior Director, MIDD Consultant

Enrica Mezzalana

See bio
Portrait-of-Moriah-Pellowe_Pharmetheus
Director, MIDD Consultant

Moriah Pellowe

See bio
Portrait-of-Marylore-Chenel_Pharmetheus
Chief Research Officer

Marylore Chenel

See bio